[1] HUDA A,ERIC JN. The neurobiology of stress: vulnerability, resilience, and major depression [J]. Proc Natl Acad Sci USA, 2023,120 (49): e2312662120
[2] 苏健婷,韦再华,高燕琳,等. 2010年北京市抑郁症疾病负担研究[J]. 首都公共卫生, 2018,12(1): 34
SU JT,WEI ZH,GAO YL,et al. Disease burden of depressive disorders in Beijing,2010 [J]. Cap J Public Health, 2018, 12(1): 34
[3] SHOKRI-MASHHADI N, DARAND M, ROUHANI MH, et al. Effects of melatonin supplementation on BDNF concentrations and depression: a systematic review and meta-analysis of randomized controlled trials [J]. Behav Brain Res, 2023, 436: e114083
[4] MONCRIEFF J, COOPER RE, STOCKMANN T, et al. The serotonin theory of depression: a systematic umbrella review of the evidence [J]. Mol Psychiatry, 2023, 28 (8): 3243
[5] THOMPSON SM, KALLARACKAL AJ, KVARTA MD, et al. An excitatory synapse hypothesis of depression [J]. Trends Neurosci, 2015, 38 (5): 279
[6] TEOH CXW, THNG M, LAU S, et al. Dry mouth effects from drugs used for depression, anxiety, schizophrenia and bipolar mood disorder in adults: systematic review [J]. Bjpsych Open, 2023, 9 (2): A63
[7] COVINGTON HE, VIALOU V, NESTLER EJ. From synapse to nucleus: novel targets for treating depression [J]. Neuropharmacology, 2010, 58 (4-5): 683
[8] BOLCHAKOV AP, ROZOV AV. Mechanisms of facilitation and depression in CNS synapses: presynaptic and postsynaptic components [J]. Neurochem J, 2014, 8 (4): 238
[9] VON WERNE BAES C, DE CARVALHO TOFOLI SM, MARTINS CMS, et al. Assessment of the hypothalamic-pituitary-adrenal axis activity: glucocorticoid receptor and mineralocorticoid receptor function in depression with early life stress-a systematic review [J]. Acta Neuropsychiatr, 2012, 24 (1): 4
[10] ANACKER C, ZUNSZAIN PA, CARVALHO LA, et al. The glucocorticoid receptor: pivot of depression and of antidepressant treatment [J]. Psychoneuroendocrinology, 2011, 36 (3): 415
[11] YU X, WANG X, LEI F, et al. The antidepressive effect of the complex consisting of Radix Pseudostellariae, Radix Pueraria and Herba Epimedii: the involvement of NRSF/NRSE-TPH2 signaling [J]. J Chin Pharm Sci, 2021, 30 (1): 27
[12] 潘平康,张超,吴海琴,等. 葛根素对大鼠脑缺血后海马中EPO和STAT-5表达的影响 [J]. 卒中与神经疾病, 2013, 20 (3): 137
PAN PK, ZHANG C, WU HQ, et al. Effects of puerarin on the expression of erythropoietin and STAT-5 in the hippocampus of cerebral ischemia injuryed in rat[J]. Stroke Nerv Dis, 2013, 20 (3): 137
[13] 夏友华. 葛根素治疗脑梗死的临床效果 [J]. 中国农村卫生, 2020, 12 (12): 31
XIA YH. Clinical effect of puerarin on cerebral infarction[J]. Chin Rural Health, 2020, 12 (12): 31
[14] 史文珍,王倩,熊婧,等. 葛根素改善卒中后抑郁大鼠行为学的研究 [J]. 临床医学研究与实践, 2019, 4 (10): 1
SHI WZ, WANG Q, XIONG J, et al. Study of puerarin on behaviour of rats with post-stroke depression[J]. Clin Res Pract, 2019, 4 (10): 1
[15] GAO LN, YAN M, ZHOU L, et al. Puerarin alleviates depression-like behavior induced by high-fat diet combined with chronic unpredictable mild stress via repairing TLR4-induced inflammatory damages and phospholipid metabolism disorders[J]. Front Pharmacol, 2021,12:e767333
[16] 张聪,胡楚璇,李穗华,等. 葛根素对慢性不可预知温和刺激大鼠抑郁行为的影响及其机制 [J]. 药学学报, 2018, 53 (2): 220
ZHANG C, HU CX, LI SH, et al. Anti-depressant effects of puerarin on depression induced by chronic unpredicted mild stress in rats[J]. Acta Pharm Sin, 2018, 53 (2): 220
[17] LIU R, LI Y, WANG Z, et al. Puerarin mitigates symptoms of depression in ovariectomized female rats by regulating hippocampal cAMP-CREB-BDNF signaling pathway[J]. Trop J Pharm Res, 2021, 20 (7): 1403
[18] SONG X, WANG W, DING S, et al. Puerarin ameliorates depression-like behaviors of with chronic unpredictable mild stress mice by remodeling their gut microbiota[J]. J Affective Disord, 2021, 290: 353
[19] LIU B, XU C, WU X, et al. Icariin exerts an antidepressant effect in an unpredictable chronic mild stress model of depression in rats and is associated with the regulation of hippocampal neuroinflammation[J]. Neuroscience, 2015, 294:193
[20] WU X, ZHANG X, SUN L, et al. Icariin prevents depression-like behaviors in chronic unpredictable mild stress-induced rats through Bax/cytoplasm C/caspase-3 axis to alleviate neuronal apoptosis[J]. Cell Mol Biol, 2023, 69 (7): 196
[21] 张聪,卢慧勤,胡楚璇,等. 淫羊藿苷对慢性不可预知温和刺激诱导的大鼠抑郁行为和神经递质水平的影响 [J]. 中国药学杂志, 2018, 53 (15): 1280
ZHANG C,LU HQ,HU CX, et al. Effect of icariin on behavior and monoamine neurotransmitters in rats with depression induced by chronic unpredicted mild stress[J]. Chin Pharm J, 2018, 53 (15): 1280
[22] DI X, WAN M, BAI YN, et al. Exploring the mechanism of Icariin in the treatment of depression through BDNF-TrkB pathway based on network pharmacology[J]. Naunyn Schmiedebergs Arch Pharmacol, 2024,397 (1): 463
[23] GONG MJ, HAN B, WANG SM, et al. Icariin reverses corticosterone-induced depression-like behavior, decrease in hippocampal brain-derived neurotrophic factor (BDNF) and metabolic network disturbances revealed by NMR-based metabonomics in rats[J]. J Pharm Biom Anal, 2016, 123: 63
[24] CAO LH, QIAO JY, HUANG HY, et al. PI3K-AKT signaling activation and icariin: the potential effects on the perimenopausal depression-like rat model[J]. Molecules, 2019, 24 (20): e3700
[25] ZENG NX, LI HZ, WANG HZ, et al. Exploration of the mechanism by which icariin modulates hippocampal neurogenesis in a rat model of depression[J]. Neural Regen Res, 2022, 17 (3): 632
[26] KONG H, WANG X, SHI R, et al. Pharmacokinetics and tissue distribution kinetics of puerarin in rats using indirect competitive ELISA[J]. Molecules, 2017, 22 (6): e939
[27] JUNG HR, KIM SJ, HAM SH, et al. Simultaneous determination of puerarin and its active metabolite in human plasma by UPLC-MS/MS: application to a pharmacokinetic study[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2014, 971: 64
[28] ZHANG G, JI J, SUN M, et al. Comparative pharmacokinetic profiles of puerarin in rat plasma by UHPLC-MS/MS after oral administration of pueraria lobata extract and pure puerarin[J]. J Anal Methods Chem, 2020. doi:10.1155/2020/e4258156
[29] LIAO ZG, LIANG XL, ZHU JY, et al. Transport properties of puerarin and effect of extract of Radix Angelicae Dahuricae on puerarin intestinal absorption using in situ and in vitro models[J]. Phytother Res, 2014, 28(9):1288
[30] YANG B, DU S, LU Y, et al. Influence of paeoniflorin and menthol on puerarin transport across MDCK and MDCK-MDR1 cells as blood–brain barrier in vitro model[J]. J Pharm Pharmacol, 2018, 70(3): 349
[31] WU JY, LI YJ, YANG L, et al. Borneol and a-asarone as adjuvant agents for improving blood-brain barrier permeability of puerarin and tetramethylpyrazine by activating adenosine receptors[J]. Drug Deliv, 2018, 25 (1): 1858
[32] LIU W, LI X, LI N, et al. UPLC-MS/MS method for icariin and metabolites in whole blood of C57 mice: development, validation, and pharmacokinetics study[J]. Front Pharmacol, 2023, 14: e1195525
[33] 张双庆,何梦洁,黄振武. 超高效液相色谱-串联质谱法研究淫羊藿苷在大鼠体内药代动力学 [J]. 卫生研究, 2016, 45(5): 807
ZHANG SQ,HE MJ,HUANG ZW. UPLC-MS/MS for the pharmacokinetics of icariin in rats[J]. Health Res, 2016, 45(5): 807
[34] 叶丽卡,陈济民,刘四海,等. 淫羊藿苷在大鼠体内的药代动力学 [J]. 中国药学杂志, 1999,34 (1): 35
YE LK, CHEN JM, LIU SH, et al. Pharmacokinetics of icariin in rats[J]. Chin Pharm J, 1999, 34(1): 35
[35] XU S, YU J, ZHAN J, et al. Pharmacokinetics, tissue distribution, and metabolism study of icariin in rat[J]. Biomed Res Int, 2017, 2017: e4684962
[36] 王敏,谷元,周宇,等. 淫羊藿苷元在大鼠体内的血浆动力学和组织分布研究 [J]. 中草药, 2021, 52(10): 3030
WANG M, GU Y, ZHOU Y, et al. Pharmacokinetics and tissue distribution of icaritin after intragastric administration in rats[J]. Chin Tradit Herb Drugs, 2021, 52(10): 3030
[37] 慈小燕,孙英辉,武卫党,等. 淫羊藿苷元的肠道跨膜转运机制研究 [J]. 中草药, 2022, 53 (9): 2747
CI XY, SUN YH, WU WD, et al. Study on transmembrane transport mechanism of icariin in intestine[J]. Chin Tradit Herb Drugs, 2022, 53 (9): 2747
[38] 梁媛, 葛若衡, 舒畅. 基于LC-MS/MS方法的大鼠血浆中舒必利的血药浓度检测及药代动力学研究 [J]. 中南药学, 2023, 21 (11): 2875
LIANG Y, GE RH, SHU C. Determination of sulpiride concentration in rat plasma and pharmacokinetics by LC-MS/MS [J]. Cent South Pharm, 2023, 21 (11): 2875
[39] 李俊,余冬,王木兰,等. 基于线粒体氧化呼吸链相关调节基因探讨二甲双胍对皮质酮致小鼠抑郁样行为的作用[J]. 中国比较医学杂志, 2023, 33 (8): 95
LI J, YU D, WANG ML, et al. Effect of metformin on corticosterone-induced depression-like behavior in mice involves genes of the mitochondrial respiratory chain [J]. Chin J Comp Med, 2023, 33 (8): 95
[40] YUAN Z, LU X, LEI F, et al. Novel effect of p-Coumaric acid on hepatic lipolysis: inhibition of hepatic lipid-droplets [J]. Molecules, 2023, 28 (12): e 4641
[41] SOGA T, NAKAJIMA S, KAWAGUCHI M, et al. Repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) in social stress and depression [J]. Prog Neuropsychopharmacol Biol Psychiatry, 2021, 104: e110053
[42] WANG XF, YU PP, LU PH. NRSE.NRSF and their modulatory effects on the expression of neuronal-specific genes[J]. Prog Biochem Biophys, 2005, 32 (7): 595
[43] THOMPSON R, CHAN C. NRSF and its epigenetic effectors: new treatments for neurological disease [J]. Brain Sci, 2018, 8 (12): e226
[44] SONG Z, ZHAO D, ZHAO H, et al. NRSF: an angel or a devil in neurogenesis and neurological diseases [J]. J Mol Neurosci, 2015, 56 (1): e131
[45] PISANI A, PACIELLO F, DEL VECCHIO V, et al. The role of BDNF as a biomarker in cognitive and sensory neurodegeneration [J]. J Pers Med, 2023, 13 (4): e652
[46] DU X, WU YC, HILL RA, et al. BDNF-TrkB signaling as a therapeutic target in neuropsychiatric disorders [J]. J Recept Ligand Channel Res, 2014, 7: 61
[47] GUO W, NAGAPPAN G, LU B. Differential effects of transient and sustained activation of BDNF-TrkB signaling [J]. Dev Neurobiol, 2018, 78 (7): 647
[48] CORREIA AS, CARDOSO A, VALE N. BDNF unveiled: exploring its role in major depression disorder serotonergic imbalance and associated stress conditions [J]. Pharmaceutics, 2023, 15 (8): e2081
[49] JIN W. Regulation of bdnf‐trkb signaling and potential therapeutic strategies for Parkinson’s disease [J]. J Clin Med, 2020, 9 (1): e257
[50] TEJEDA GS, DIAZ-GUERRA M. Integral characterization of defective BDNF/TrkB signalling in neurological and psychiatric disorders leads the way to new therapies [J]. Int J Mol Sci, 2017, 18 (2): e268
[51] LIU Y, HU Z, WANG J, et al. Puerarin alleviates depressive-like behaviors in high-fat diet-induced diabetic mice via modulating hippocampal GLP-1R/BDNF/TrkB signaling [J]. Nutr Neurosci, 2023, 26 (10): 997
[52] HONG M. Biochemical studies on the structure-function relationship of major drug transporters in the ATP-binding cassette family and solute carrier family [J]. Adv Drug Deliv Rev, 2017, 116: 3
[53] MORIYA Y, KASAHARA Y, SHIMADA M, et al. Role for μ-opioid receptor in antidepressant effects of δ-opioid receptor agonist KNT-127[J]. J Pharmacol Sci, 2023,151 (3): 135
[54] REN F, MA Y, ZHU X, et al. Pharmacogenetic association of bi- and triallelic polymorphisms of SLC6A4 with antidepressant response in major depressive disorder [J]. J Affective Disord, 2020, 273: 254
[55] RHEN T, CIDLOWSKI JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs [J]. N Engl J Med, 2005, 353 (16): 1711
[56] SIONOV RV, KFIR S, ZAFRIR E, et al. Glucocorticoid-induced apoptosis revisited: a novel role for glucocorticoid receptor translocation to the mitochondria [J]. Cell Cycle, 2006, 5 (10): 1017
[57] LU NZ, CIDLOWSKI JA. Glucocorticoid receptor isoforms generate transcription specificity [J]. Trends Cell Biol, 2006, 16 (6): 301
[58] HERMAN JP, SEROOGY K. Hypothalamic-pituitary-adrenal Axis, glucocorticoids, and neurologic disease [J]. Neurol Clin, 2006, 24 (3): 461
[59] WANG Y, ZHUANG Y, DIBERTO JF, et al. Structures of the entire human opioid receptor family [J]. Cell, 2023, 186 (2):413
[60] SHIRAKI A, SHIMIZU S. The molecular associations in clathrin-coated pit regulate β-arrestin-mediated MAPK signaling downstream of μ-opioid receptor [J]. Biochem Biophys Res Commun, 2023, 640:64
[61] GAMBLE MC, WILLIAMS BR, SINGH N, et al. Mu-opioid receptor and receptor tyrosine kinase crosstalk: implications in mechanisms of opioid tolerance, reduced analgesia to neuropathic pain, dependence, and reward [J]. Front Syst Neurosci, 2022, 16: e1059089
[62] MORIYA Y, KASAHARA Y, SHIMADA M, et al. Role for μ-opioid receptor in antidepressant effects of δ-opioid receptor agonist KNT-127 [J]. J Pharmacol Sci, 2023,151 (3):135
[63] 卢弘, 李敏, 邢东明, 等. 对中药复方药代动力学研究中血药浓度测定方法的评述与思考[J]. 世界科学技术-中医药现代化, 2000, 3(4): 22
LU H, LI M, XING DM, et al. Comment on the test method of plasma concentration in pharmacokinetics of Chinese herbal compound[J]. World Sci Technol Mod Tradit Chin Med, 2000, 3(4): 22
[64] 杜力军, 邢东明, 炎彬, 等. 对葛根素与葛根黄酮体内动力学关系的探讨-兼论中药药代动力学的研究方法[J]. 世界科学技术-中医药现代化, 2004, 6(6): 26
DU LJ, XING DM, YAN B, et al. Exploration of relationship between in vivo dynamics of puerarin and flovone of root of Kutzu vine and a discussion on study method of pharmacokinetics of Chinese medicines [J]. World Sci Technol Mod Tradit Chin Med, 2004,6 (6): 26
